Mnemosyne Pharmaceuticals, Inc. is developing an innovative drug discovery platform that will address medical needs in several segments of the mental health market.
Mnemosyne was founded in 2010 with seed funding from Slater Technology Fund and private investors. Recently, Mnemosyne closed on a Series A round totaling $5.4M. Mnemosyne is using these funds to develop a new class of small molecule drugs that modulate the activity of different subtypes of the NMDA receptor.
Funding Rounds (2) - $11.4MUpdate
Powering Tomorrow's Biopharma Companies
Early Stage Tech and Life Sciences
Access Industries is a privately held industrial group with long-term holdings worldwide
Slater Technology Fund is a venture capital firm investing in technology-based startup companies...
One Davol Square
Providence, RI 02903